A germ cell tumor is a growth that develops from the cells your body originally set aside to become eggs or sperm. These tumors most commonly appear in the testicles or ovaries, but they can also form in the chest, abdomen, or brain. They range from completely benign to highly aggressive, though even advanced cases often respond well to treatment, with five-year survival rates above 95% for early-stage disease.
Where Germ Cell Tumors Come From
Early in embryonic development, your body creates a set of precursor cells called primordial germ cells. These cells are supposed to migrate from the center of the embryo to the developing reproductive organs (the “genital ridge”), where they’ll eventually mature into eggs or sperm. Germ cell tumors arise when something goes wrong during that migration or after the cells arrive. The cells pick up genetic or epigenetic errors that cause them to grow uncontrollably instead of maturing normally.
Because these precursor cells travel through the body during development, they sometimes settle in the wrong place. That’s why germ cell tumors can appear outside the reproductive organs entirely. In adults, the most common non-gonadal site is the mediastinum, the central compartment of the chest between the lungs. The retroperitoneum, the space behind the abdominal organs near the spine, is the second most common. In children, germ cell tumors can also develop at the base of the spine (the sacrococcygeal region) or inside the brain, particularly near the pineal gland. Roughly 5% to 10% of all germ cell cancers arise in these non-gonadal locations.
Types of Germ Cell Tumors
Germ cell tumors fall into two broad categories: seminomas and non-seminomas. This distinction matters because the two types behave differently and require different treatment approaches.
Seminomas
Seminomas are the most common type. They tend to grow more slowly and are highly sensitive to radiation therapy. They typically appear in men between their late 30s and early 50s. Pure seminomas do not produce a protein called alpha-fetoprotein (AFP), so if AFP is elevated in someone diagnosed with what looks like a seminoma, it signals that non-seminoma cells are present too.
Non-Seminomas
Non-seminomas are a group of subtypes, each with distinct characteristics:
- Embryonal carcinoma consists of primitive, undifferentiated cells that resemble very early embryonic tissue. These tumors are aggressive and can produce both AFP and another marker called beta-HCG.
- Yolk sac tumors (also called endodermal sinus tumors) grow in glandular or cystic patterns and typically produce AFP. They’re the most common testicular tumor in young children but rare as a pure form in adults.
- Choriocarcinoma is the rarest and most aggressive subtype. It tends to spread quickly through the bloodstream and produces high levels of beta-HCG.
- Teratomas contain a mix of tissue types, sometimes including hair, bone, or teeth, because the tumor cells differentiate into tissues from all three embryonic layers. Mature teratomas are generally benign, especially in women. Immature teratomas contain poorly developed tissue, most often primitive nerve tissue, and are graded based on how much immature tissue they contain. Higher grades carry a worse prognosis.
Many germ cell tumors are actually a mix of these subtypes. A single tumor can contain seminoma and non-seminoma elements, and when it does, it’s treated as a non-seminoma because of the more aggressive component.
Symptoms by Location
What a germ cell tumor feels like depends almost entirely on where it’s growing. A testicular germ cell tumor usually shows up as a painless lump or swelling in one testicle, sometimes with a dull ache in the scrotum or lower abdomen. An ovarian germ cell tumor can cause pelvic pain, back pain, bloating, or visible swelling in the belly.
Tumors in the chest can press on the airways or major blood vessels, causing shortness of breath, chest pain, or a persistent cough. Germ cell tumors in the brain may cause headaches, vision changes, nausea, or hormonal disruptions depending on which structures they compress. Because many of these symptoms overlap with common, less serious conditions, germ cell tumors are sometimes discovered late, particularly when they occur outside the reproductive organs.
Who Is at Higher Risk
The strongest known risk factor for testicular germ cell tumors is cryptorchidism, a condition where one or both testicles fail to descend into the scrotum during development. About 3% of boys are born with an undescended testicle. The cancer risk in that undescended testicle is four to six times higher than normal, and even the other testicle carries a slightly elevated risk. Surgery to move the testicle into the scrotum before puberty reduces the risk (bringing it down to about two to three times the general population) but doesn’t eliminate it.
Family history plays a significant role. Having a brother with testicular cancer raises your risk eight to twelvefold. Having a father with it raises the risk two to fourfold. Men who’ve already had testicular cancer face the highest risk of developing it in the other testicle, though only about 2% actually do. A precancerous condition called germ cell neoplasia in situ (GCNIS), sometimes found incidentally during other procedures, carries a 50% chance of progressing to cancer within five years and 70% within seven years.
How Germ Cell Tumors Are Diagnosed
Diagnosis typically starts with imaging, usually an ultrasound for testicular masses or CT scans for tumors elsewhere. But blood tests for three specific tumor markers play an unusually important role in germ cell tumors compared to most other cancers.
AFP is produced mainly by yolk sac tumor components. Beta-HCG is made by cells found in both seminomas and non-seminomas, though it’s especially high in choriocarcinomas. A third marker, LDH, is less specific since it’s released whenever cells die anywhere in the body, but it helps gauge how much tumor is present. In non-seminomas, at least one of these three markers is elevated in about 82% of cases at diagnosis. Seminomas are less likely to show marker elevation, with any marker abnormal in about 45% of patients.
These markers aren’t just useful for diagnosis. Doctors track them after treatment to monitor whether the tumor is responding and during follow-up to catch recurrences early, sometimes before a tumor is even visible on scans.
Treatment Approaches
Germ cell tumors are among the most treatable solid cancers, even when they’ve spread. Treatment depends on the tumor type, stage, and risk category.
For testicular germ cell tumors, the first step is almost always surgical removal of the affected testicle through an incision in the groin (not the scrotum). For small, ambiguous masses under 2 centimeters in men with only one functioning testicle, surgeons may sometimes remove just the tumor and preserve the rest of the testicle. After surgery, many men with early-stage disease can be managed with careful surveillance alone, meaning regular blood tests and imaging rather than immediate additional treatment. The relapse rate from early-stage disease is around 10%, and relapses are almost always caught and cured.
When the cancer has spread or when the risk of recurrence is higher, treatment involves platinum-based chemotherapy. The standard regimen combines three drugs and is given in cycles over several weeks. For good-risk metastatic disease, three cycles are standard. For intermediate or poor-risk disease, treatment is more intensive with four cycles or alternative combinations. Radiation therapy is sometimes used for seminomas that have spread to nearby lymph nodes, particularly when the involved nodes are small.
Some patients need additional surgery after chemotherapy to remove residual masses, especially in non-seminomas where teratoma tissue can remain even after chemotherapy has eliminated the more aggressive components.
Survival and Prognosis
Germ cell tumors have some of the best survival rates of any cancer. Early-stage testicular cancer that hasn’t spread beyond the testicle is cured in the vast majority of cases. Even when the cancer has metastasized, outcomes are remarkably good compared to other advanced cancers.
Survival depends heavily on the risk category at diagnosis. For metastatic seminomas, the five-year survival rate is 100% in the good-risk group and about 88% in the intermediate-risk group. For metastatic non-seminomas, the five-year rates are roughly 97% for good-risk, 87% for intermediate-risk, and 65% for poor-risk disease. The risk classification is based on where the cancer has spread, which organs are involved, and how high the tumor markers are.
Ovarian germ cell tumors also carry a favorable prognosis overall, though outcomes vary more by subtype. Mature teratomas in the ovary are benign and cured by surgery alone. Immature teratomas and other malignant ovarian germ cell tumors generally respond well to the same platinum-based chemotherapy used for testicular cancers.
Fertility After Treatment
Because germ cell tumors primarily affect young people of reproductive age, fertility preservation is a critical part of treatment planning. Chemotherapy and radiation can both impair the ability to produce healthy eggs or sperm, sometimes temporarily and sometimes permanently.
Current guidelines recommend that fertility risks be discussed before any cancer treatment begins. For men, sperm banking (cryopreservation) should be offered before surgery or chemotherapy starts. For women, options include freezing eggs, embryos, or ovarian tissue. In prepubertal boys, testicular tissue cryopreservation is still experimental and available only through clinical trials. For prepubertal girls, ovarian tissue cryopreservation is the only established option.
Even when patients don’t ultimately pursue fertility preservation, having the conversation early reduces long-term distress about reproductive options. Fertility discussions should continue during survivorship follow-up, particularly as treatment plans change or when someone is considering pregnancy. Men are generally advised to wait after completing chemotherapy before attempting conception, since sperm quality can be temporarily affected by genetic damage from treatment.